Length 160 pages

Date published May 2009

Print copies are available upon request. Call 781-972-5444. 

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 


IPR-Bundle-Button 

Approaches to Reducing Phase II Attrition Overview

 

Report CoverApproaches to Reducing Phase II Attrition

Author: Allan B. Haberman, PhD

 

 


 

Phase II is the critical development stage in which most clinical attrition occurs. This report focuses on approaches to improving R&D productivity in the pharmaceutical and biotechnology industries and considers:

  • Leading-edge strategies being pursued to improve success rates of therapeutic candidates in clinical development
  • The use of translational medicine studies and early clinical trial protocols designed to reduce Phase II attrition
  • Survey results and expert interviews on efforts to improve R&D efficiency.
 

Pharmaceutical companies have been responding to a combination of major challenges that many commentators call a “perfect storm.” It is clear that the high rate of attrition in the drug development process is severely limiting the numbers of high-quality novel drug candidates, especially for innovative drugs that address unmet medical needs. In order to overcome this limitation, the industry must develop strategies that can reduce attrition during Phase II, where most attrition occurs, especially as it continues to drive up the cost of R&D to unsustainable levels.

Approaches to Reducing Phase II Attrition considers examples of leading-edge strategies being pursued to improve target selection and other aspects of drug discovery. These include development of multitargeted therapies, whole-pathway approaches, biology-driven drug discovery, analysis of multigenic complex diseases, and network pharmacology. Strategies for improving early-stage clinical studies are discussed, including the use of Phase 0 and adaptive trials, and employing early proof-of-concept trials. Ways in which some companies have adopted new corporate structures designed to increase innovation or make R&D more “biotech-like” are described.

table 

Poorly predictive animal models constitute a major cause of drug attrition. We present two case studies in CNS and cancer, two therapeutic areas in which animal models are notorious for being poorly predictive. The CNS case study focuses on attempts to improve animal model efficacy studies, and the cancer case study focuses on industry’s adoption of improved animal models developed in academia. In these discussions, we indicate how these particular case studies may have lessons for efficacy studies in most therapeutic areas.

Well-designed translational studies may enable drugs that do not work in humans to fail early. We examine various aspects of translational studies, including definition of responder versus non-responder populations, and optimal dosing regimens; and identification of early and sensitive markers of efficacy, and of those patients who are likely to experience adverse effects. Examples of ways in which translational medicine is changing the organization of clinical trials in some companies are discussed. We also study the roles that various types of biomarkers play in translational medicine, as well as the current state of biomarker science. Case studies on stratification biomarkers in cancer are presented.

Approaches to Reducing Phase II Attrition analyzes results from a survey of current practices and views toward improving the efficiency and effectiveness of drug development. Finally, the complete transcripts of interviews conducted with experts in the field are provided.

About the Author
Allan B. Haberman, PhD, is Principal of Haberman Associates, a consulting firm specializing in science and tech¬nology strategy for pharmaceutical, biotechnology, and other life science companies. He is also a Principal and Founder of the Biophar¬maceutical Consortium (www.biopharmconsortium.com), an expert team formed to assist life science companies, research groups, and emerging enterprises to identify and exploit promising, breakthrough technologies. He is also the author of numerous publications on the pharmaceutical and biotechnology industries, their technologies and products, and on the major therapeutic areas for drug discovery and development. Formerly the associate director of the Biotechnology Engineering Center at Tufts University, he received his PhD in biochemistry and molecular biology from Harvard University.